Many organisations see regulatory planning as a compliance exercise. For early-stage MedTech companies, a credible regulatory and clinical roadmap can play an important role in product development, funding discussions and stakeholder confidence.
Too often, early plans are built on assumptions that have not been properly verified. A structured, evidence-based approach can help identify business risks, improve risk transparency and support investor confidence.
In this 60-minute webinar, TÜV SÜD experts will share practical considerations for developing regulatory and clinical roadmaps and explain how evidence-based planning can strengthen your business case.
Your regulatory and clinical roadmap is more than a planning document. It can help you identify assumptions, understand risks and support more informed business decisions.
After watching this webinar, you will be better equipped to:
This webinar is designed for early-stage MedTech companies and professionals involved in regulatory planning, product development and investment decision-making.
It is particularly relevant for:
This webinar is especially useful if you are:
Malte Knowles Schmidt - Global Portfolio Manager, TÜV SÜD Medical Health Services
Malte moderates the discussion and guides participants through key topics related to regulatory and clinical roadmap development for MedTech start-ups.
Ralf Gansel - Head of Sales, TÜV SÜD Medical Health Services
Ralf contributes perspectives on regulatory planning considerations and roadmap development throughout the product lifecycle.
Julia Hoyer - Head of Regulatory Affairs, TÜV SÜD Medical Health Services
Julia shares insights related to regulatory planning, roadmap development, and certification planning considerations.
This webinar is in a three-part series focused on helping MedTech organisations understand how regulatory decisions can be used as a business asset, not a blocker throughout their development journey.
This webinar forms part of TÜV SÜD's broader Start-up & Investors Initiative, designed to help MedTech startups and investors understand how to make key regulatory decisions that impact business risks and commercialisation.
